Visit Our Sponsors
The drugmaker announced the expanded recall earlier this month. According to the FDA, Mylan is voluntarily recalling the 0.3 mg and 0.15 mg strengths of EpiPen and EpiPen Jr. Auto-Injector because of a problem that may keep them from activating. The recall does not include any of its Mylan's new authorized generic EpiPens, the FDA said.
The first recall was for Japan, Australia and some markets in Europe. Now it has been expanded to the U.S. as well as additional markets in Europe, Asia and North and South America. Mylan did not specify exactly how many of the Pfizer-made pens are being retrieved this time around, only that the recall involves 13 lots, That is more than three times the number of lots recalled last month when it said more than 80,000 pens were involved.
“Mylan has an adequate supply to replace the recalled devices, as well as to continue to supply the market for future demand of new prescriptions,” a Mylan spokesperson said in an email.
The recalls were initially triggered after Mylan received two confirmed reports of pens that failed to activate because of a potential defect in a supplier component, raising concerns some units would malfunction during an emergency. The pens are manufactured by Pfizer’s Meridian Medical Technologies unit in St. Louis, Missouri.
Enjoy curated articles directly to your inbox.